Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNA7 | P36544 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | RAD52 | P43351 | 2/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | AGXT | P21549 | 2/20 | 0.50 |
| ▸ | KHK | P50053 | 2/20 | 0.48 |
| ▸ | DRD2 | P14416 | 5/20 | 0.48 |
| ▸ | DRD3 | P35462 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.45 |
| ▸ | DRD4 | P21917 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27662780 | 0.88 | AGXT (0.56) | MAPTSMN1; SMN2AGXTDRD2DRD3 | |
| SCHEMBL109344 | 0.83 | AGXT (0.69) | GAARAD52KDM4EMAPTGFER | |
| SCHEMBL2377738 | 0.83 | GAA (0.68) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL6263381 | 0.83 | DRD4 (0.70) | KDM4EMAPTSMN1; SMN2DRD2DRD3 | |
| SCHEMBL30647354 | 0.81 | GAA (0.66) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL1126080 | 0.81 | GAA (0.66) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL4577574 | 0.81 | CHRNA7 (0.56) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL8352129 | 0.81 | CHRNA7 (0.56) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL4577571 | 0.81 | CHRNA7 (0.56) | CHRNA7GAARAD52KDM4EMAPT | |
| SCHEMBL109316 | 0.81 | AGXT (0.67) | GAARAD52KDM4EMAPTAGXT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050749-B1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2017-11-22 | — | — | EP | disclosed |
| US-8022205-B2 | Pyrimidine derivatives as PI3K inhibitor and use thereof | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-09-20 | — | — | US | disclosed |
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-03-18 | — | — | US | disclosed |
| EP-2050749-A1 | PYRIMIDINE DERIVATIVE AS PI3K INHIBITOR AND USE THEREOF | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069629-A1 | PYRIMIDINE DERIVATIVES AS PI3K INHIBITOR AND USE THEREOF | PIK3CA, AKT3, AKT1 | CHRNA7 4804/4885GAA 2827/4885RAD52 2095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.